Microbiological researchJun 13, 2026

Changing effects of gut bacteria chemicals in Alzheimer's disease and what they mean for gut-brain treatments

Gut-Brain Axis Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 16, 2026

Abstract

The microbiome-gut-brain axis (MGBA) plays a crucial regulatory role in Alzheimer's disease (AD) through microbial metabolites.

Metabolite concentration trajectories vary across different stages of Alzheimer's disease and bodily compartments.
Gut dysbiosis may accelerate neurodegeneration by altering metabolite signaling.
AD-related brain changes could disrupt gut health, indicating a bidirectional relationship between gut and brain.
Current intervention strategies targeting the MGBA face limitations such as unclear dose-response relationships.
Evidence for how brain pathology affects gut health is less developed than the reverse relationship.
Future research should focus on linking neuroendocrine and immune pathways to gut dysbiosis and investigate the effects of specific metabolites.

Simplified

Alzheimer's disease (AD) is a complex neurodegenerative disorder in which the microbiome-gut-brain axis (MGBA) plays a crucial regulatory role through microbial metabolites. This review analyzes the concentration trajectories of representative metabolites across different disease stages and compartments, and synthesizes current preclinical evidence on how these metabolites influence AD pathogenesis, with particular attention to the mechanisms underlying their dual roles. We integrate evidence for bidirectional pathological crosstalk: gut dysbiosis accelerates central neurodegeneration through altered metabolite signaling, while AD-related neuropathology concurrently disrupts gut homeostasis. The review also evaluates MGBA-targeted intervention strategies and critically identifies key limitations that hinder clinical translation, including unclear dose-response relationships and insufficient patient stratification. We note that brain-to-gut mechanistic evidence remains considerably less developed than that for the gut-to-brain direction, and that signaling crosstalk among multiple metabolites is poorly characterized. Future studies should prioritize the neuroendocrine and immune pathways linking central pathology to gut dysbiosis, the dose-response relationships of individual metabolites, and standardized multi-metabolite profiling within prospective longitudinal cohorts. Addressing these gaps will advance mechanism-guided, precision-targeted interventions that mitigate the prevalent gut dysfunction in AD and confer global therapeutic benefits.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of Competing Interest The authors declare no competing financial interest.

PubMed

Changing effects of gut bacteria chemicals in Alzheimer's disease and what they mean for gut-brain treatments

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the gut-brain axis brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the gut-brain axis brief